These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 20973707

  • 1. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
    Findling RL, Katic A, Rubin R, Moon E, Civil R, Li Y.
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):365-75. PubMed ID: 20973707
    [Abstract] [Full Text] [Related]

  • 2. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [Abstract] [Full Text] [Related]

  • 3. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [Abstract] [Full Text] [Related]

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 5. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system.
    Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P.
    Curr Med Res Opin; 2009 Dec; 25(12):3001-10. PubMed ID: 19849639
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, Caballero B, Zuddas A.
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE.
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
    Childress AC, Marraffino A, Cutler AJ, Oh C, Brams MN.
    J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):51-58. PubMed ID: 36809150
    [Abstract] [Full Text] [Related]

  • 14. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
    Anderson VR, Scott LJ.
    Drugs; 2006 Apr; 66(8):1117-26. PubMed ID: 16789796
    [Abstract] [Full Text] [Related]

  • 18. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
    Golubchik P, Sever J, Zalsman G, Weizman A.
    Int Clin Psychopharmacol; 2008 Jul; 23(4):228-31. PubMed ID: 18446088
    [Abstract] [Full Text] [Related]

  • 19. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S.
    Acta Med Iran; 2012 Jul; 50(11):723-8. PubMed ID: 23292622
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E.
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.